Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug
02:40pm, Monday, 15'th Aug 2022 Zacks Investment Research
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.
Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says
06:42am, Monday, 15'th Aug 2022 MarketWatch
AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial.
AstraZeneca breast cancer drug performs well in latest trial
03:32am, Monday, 15'th Aug 2022
Enhertu, AstraZeneca PLC (LSE:AZN)'s drug for women with HER2-positive breast cancer, delivered a statistically significant and clinically meaningful improvement in progression-free survival in the la
Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says
02:42am, Monday, 15'th Aug 2022
By Kyle Morris
Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023
01:50pm, Friday, 12'th Aug 2022 Zacks Investment Research
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
AstraZeneca chemotherapy signed off for use in people with lung cancer
03:39am, Friday, 12'th Aug 2022
AstraZeneca PLC (LSE:AZN) said its drug Enhertu has been given the green light in the US to be given to patients with advanced and difficult-to-treat non-small cell lung cancer. The Food & Drug Admini
This Analyst Says Zentalis' Increased Focus On WEE1 Program Is 'Prudent', Slashes Price Target By 37%
08:39pm, Wednesday, 10'th Aug 2022 Benzinga
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) decided to discontinue the development of oral SERD asset ZN-c5 and EGFR inhibitor ZN-e4 following the completion of existing clinical trials.
The comp
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
12:14pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Apellis (APLS) Q2 Earnings and Sales Miss Estimates, Stock Down
03:52pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.
AstraZeneca breast cancer drug gets the green light
03:33am, Monday, 08'th Aug 2022
AstraZeneca PLC (LSE:AZN) hailed as ‘transformational' a breast cancer treatment that has received fast-track sign-off by the US Food & Drug Administration. Enhertu, which AZ jointly developed with
3 Unstoppable Stocks That Don't Care About the Bear Market
01:00pm, Sunday, 07'th Aug 2022 The Motley Fool
When the market is falling, this trio keeps rising.
3 Unstoppable Stocks That Don't Care About the Bear Market
09:00am, Sunday, 07'th Aug 2022
When the market is falling, this trio keeps rising.
Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance
03:45pm, Friday, 05'th Aug 2022 Zacks Investment Research
Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.
3 Pharma Stocks' Post-Earnings Price Moves
06:06am, Thursday, 04'th Aug 2022
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program
04:47pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.
